1-3 of 3
Beray Kazak
Close
Sort by
Journal Articles

Next-Generation Sequencing (NGS) in CMML, MDS and AML Detects Molecular Mutations in Oncogenes and Allows the Identification of Balanced Chromosomal Abnormalities with Extraordinary Sensitivity and Specificity.

Vera Grossmann, MA, Alexander Kohlmann, PhD, Claudia Haferlach, MD, Hans-Ulrich Klein, MA, Martin Dugas, MD, Frank Dicker, PhD, Beray Kazak, Sonja Schindela, Susanne Schnittger, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD
Journal: Blood
Blood (2009) 114 (22): 144.
https://doi.org/10.1182/blood.V114.22.144.144
Published: 2009
Journal Articles

An Accumulation of Cytogenetic and Molecular Genetic Events Characterizes the Progression From MDS to Secondary AML: An Analysis of Paired Samples in 38 Patients Analyzed by Cytogenetics, Mutation Analysis and SNP Microarrays.

Johanna Flach, Sonja Schindela, Frank Dicker, PhD, Susanne Schnittger, PhD, Beray Kazak, Alexander Kohlmann, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD
Journal: Blood
Blood (2009) 114 (22): 1748.
https://doi.org/10.1182/blood.V114.22.1748.1748
Published: 2009
Journal Articles

Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 75% of Chronic Myelomonocytic Leukemia (CMML) by Detecting Frequent Alterations in TET2 , RUNX1 , CBL , and RAS .

Alexander Kohlmann, PhD, Vera Grossmann, MA, Claudia Haferlach, MD, Beray Kazak, Sonja Schindela, Hans-Ulrich Klein, Tamara Weiss, Frank Dicker, PhD, Susanne Schnittger, PhD, Martin Dugas, MD, Wolfgang Kern, MD, Torsten Haferlach, MD
Journal: Blood
Blood (2009) 114 (22): 417.
https://doi.org/10.1182/blood.V114.22.417.417
Published: 2009